Virtu Financial LLC Tg Therapeutics, Inc. Transaction History

Virtu Financial LLC

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 01, 2023	BUY	$10.23 - $19.34 $217,121 - $410,472	21,224 New	21,224 $319,000
Q2 2022 Aug 09, 2022	SELL	$3.74 - $10.66 $31,318 - $89,266	-8,374 Reduced 40.72%	12,191 $52,000
Q1 2022 May 17, 2022	BUY	$7.81 - $20.45 $160,612 - $420,554	20,565 New	20,565 $196,000
Q3 2021 Nov 12, 2021	SELL	$21.78 - $40.45 $141,417 - $262,641	-6,493 Closed	0 $0
Q2 2021 Sep 17, 2021	BUY	$32.5 - $48.96 $211,022 - $317,897	6,493 New	6,493 $252,000
Q1 2021 May 19, 2021	SELL	$41.61 - $54.3 $721,101 - $941,019	-17,330 Closed	0 $0
Q4 2020 Feb 24, 2021	BUY	$25.27 - $54.9 $437,929 - $951,417	17,330 New	17,330 $902,000
Q3 2020 Dec 11, 2020	SELL	$18.49 - $27.24 $193,719 - $285,393	-10,477 Closed	0 $0
Q2 2020 Aug 07, 2020	SELL	$8.9 - $21.84 $196,458 - $482,096	-22,074 Reduced 67.81%	10,477 $204,000
Q4 2019 Feb 04, 2020	BUY	$5.1 - $11.2 $103,417 - $227,113	20,278 Added 165.22%	32,551 $361,000
Q3 2019 Nov 20, 2019	BUY	$5.38 - $8.99 $66,028 - $110,334	12,273 New	12,273 $69,000
Q1 2019 Apr 12, 2019	SELL	$4.02 - $8.04 $207,311 - $414,622	-51,570 Closed	0 $0
Q4 2018 Jan 16, 2019	BUY	$3.44 - $5.76 $141,882 - $237,571	41,245 Added 399.47%	51,570 $211,000
Q3 2018 Nov 13, 2018	SELL	$5.15 - $14.0 $135,275 - $367,738	-26,267 Reduced 71.78%	10,325 $58,000
Q1 2018 May 14, 2018	SELL	$8.7 - $16.8 $82,328 - $158,978	-9,463 Reduced 20.55%	36,592 $520,000
Q4 2017 Feb 09, 2018	BUY	$7.35 - $12.3 $190,681 - $319,098	25,943 Added 128.99%	46,055 $378,000
Q3 2017 Nov 15, 2017	BUY	$10.0 - $12.7 $201,120 - $255,422	20,112	20,112 $0

345

87.6M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.86B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.